FAYUVI’s Label Limits It to Early-Stage Sanfilippo

FAYUVI (rebisufligene etisparvovec-hopf)What to know

30-second read

For Neurology · Pediatrics

Who

Pediatric patients with MPS IIIA (Sanfilippo syndrome type A) who still have preserved neurodevelopmental function — not those already significantly declined.

What’s new

First FDA-approved treatment for the disease: a one-time IV AAV9 gene therapy delivering a working SGSH gene, replacing symptom management alone.

Evidence

Transpher A (27 treated vs. 27 natural-history controls): 23.5-point higher Bayley-III cognitive score (p<0.0001); CSF heparan sulfate fell a median 63.98% within a month.

Big advantage

One infusion, not a lifelong regimen — and standard (not accelerated) approval, on nearly a decade of accumulated follow-up data.

Key consideration

Eligibility is defined by how early the disease is caught. Hepatotoxicity in ~85% of patients requires corticosteroid prophylaxis and liver monitoring.

Availability

Approved 17 September 2026; reaching qualified U.S. centers in 30–60 days. Priced at $3.95 million WAC per patient.

Practice impactRefer early, before decline is obvious

The therapy works before neurodegeneration takes hold, not after. Developmental delay, regression or coarse facial features in a young child are now reasons to pursue genetic testing promptly — the window this approval opens closes as the disease progresses.

Read the full physician analysis

Full analysis · 8 min readFDA approval notice · Transpher A trial data · FAYUVI prescribing information

FDA approved FAYUVI (rebisufligene etisparvovec-hopf, Ultragenyx) on 17 September 2026 for the neurologic manifestations of MPS IIIA — Sanfilippo syndrome type A — in pediatric patients with preserved neurodevelopmental function. It is the first FDA-approved treatment for the disease in either sense that matters: the first therapy to address its underlying cause, and the first approved for it at all. A single intravenous infusion delivers a working copy of the gene these children are born without. What makes this approval unusual for a physician to act on is not the science — it is that the label defines eligibility by timing, not just diagnosis, and the disease does not wait for a referral.

A Disease That Erases What a Child Has Already Learned

MPS IIIA is caused by a deficiency of the enzyme that breaks down heparan sulfate, a complex sugar that, left undegraded, accumulates progressively in cells throughout the body — most damagingly in the brain. Children with the disease are typically born without obvious signs and develop close to normally through infancy. Regression follows: language and cognitive skills already acquired erode, behavior changes, sleep disturbance and seizures often appear, and physical decline follows the cognitive one. Mean age at death is commonly cited in the mid-teens, with a range that runs from before age ten to the third or fourth decade in the mildest cases. It is an ultra-rare disease — Ultragenyx has estimated 3,000 to 5,000 affected patients across the developed world — and until 17 September 2026, every treatment available was supportive: managing seizures, behavior and sleep as they emerged, with nothing addressing the underlying enzyme deficiency driving the decline.

One Infusion, Engineered to Reach the Brain

FAYUVI uses an AAV9 viral vector — a serotype capable of crossing the blood-brain barrier — to deliver a functional copy of the SGSH gene intravenously in a single dose. The intent is to let a patient's own cells begin producing the enzyme they lack, degrading accumulated heparan sulfate rather than leaving it to keep building. That is a different proposition from enzyme replacement therapy, the approach behind an earlier, ultimately discontinued attempt at treating this disease: a one-time genetic correction, rather than a therapy requiring repeated dosing to reach an enzyme that in earlier attempts often could not cross into the brain in meaningful quantities. Cerebrospinal fluid heparan sulfate levels, measured directly in Ultragenyx's trial, fell and stayed lower after treatment — the biomarker evidence behind the clinical result.

What Transpher A Actually Showed

The approval rests on Transpher A (NCT02716246), an efficacy set of 27 treated patients, dosed at 3x10^13 vg/kg, compared against an external natural-history cohort of 27 untreated patients — not a randomized, placebo-controlled design, which is difficult to justify in a fatal pediatric disease with a well-characterized decline, but a real constraint on how confidently the result can be read. Using the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) cognitive raw score as the primary measure across the 24-to-60-month study window, treated patients scored 23.5 points higher than the natural-history comparison (p<0.0001), and cerebrospinal fluid heparan sulfate — the substrate accumulation that drives the disease's neurodegeneration — fell by a median of 63.98% within the first month of treatment. A broader 33-patient safety set was followed for 0.6 to 8.5 years, a median of 4.5 years, and FDA granted standard, not accelerated, approval — a regulatory signal that the agency views the evidence as more than a surrogate awaiting confirmation. The comparison against external, rather than randomized, controls remains the honest caveat: Sanfilippo syndrome's natural history is unusually well documented, which is what makes an external-control design defensible here, but it is not the same evidentiary bar as a randomized trial.

Before and after this approval

	Before 17 September 2026	With FAYUVI
Available treatment	Supportive care only — seizures, behavior, sleep	One-time IV gene therapy addressing the enzyme deficiency
Approach to disease course	Manage symptoms as they emerge	Attempt to slow or prevent further neurodegeneration
Eligibility window	Not applicable	Preserved neurodevelopmental function at treatment — diagnosis timing decides who qualifies
Longest reported follow-up	Natural-history cohorts only	Up to 8.5 years post-treatment, median 4.5 (Transpher A safety set)
Cost	Variable, ongoing supportive costs	$3.95 million WAC, one time

Transpher A compared treated patients against an external natural-history cohort, not a randomized control arm.

A Window That Closes As the Disease Progresses

The label's defining constraint is not a dose or a contraindication — it is timing. FAYUVI is indicated for patients with MPS IIIA who have preserved neurodevelopmental function, which means a child already substantially regressed is not the population this therapy was studied in or approved for. Sanfilippo syndrome has no newborn screening program in the United States, and its early signs — mild developmental delay, coarse facial features, recurrent ear infections, hyperactivity — overlap heavily with far more common and far less serious childhood presentations. The practical effect of this approval is to convert diagnostic delay into a treatment-eligibility problem: a child diagnosed at the point where regression is already unmistakable to a family may have missed the window this therapy was designed for. That puts real weight on primary care and pediatric neurology recognizing the pattern early enough to order genetic testing before decline is obvious, not after.

The Safety Side of a Single Infusion

FAYUVI's prescribing information carries warnings and precautions for hepatotoxicity, thrombocytopenia, thrombotic microangiopathy, hypersensitivity and infusion reactions, and an increased risk of malignancy — the last a class consideration for AAV-vector gene therapies generally, tied to how the vector's genetic material can integrate into a treated cell's genome. Hepatotoxicity was the most common finding: elevated liver enzymes occurred in roughly 85% of treated patients in clinical studies, which is why the label requires corticosteroid prophylaxis beginning the day before infusion and continuing for at least eight weeks afterward, alongside baseline and ongoing liver function testing (ALT, AST, GGT and total bilirubin). Families are instructed to contact their care team immediately for jaundice or a missed or vomited corticosteroid dose — a monitoring burden that, unlike a chronic medication's routine labs, is front-loaded into a narrow window around a single irreversible infusion.

• Treat unexplained developmental delay or regression as a referral trigger, not a wait-and-watch presentation — the therapy's eligibility depends on catching the disease before decline is advanced.
• Confirm access to an infusion-capable center before counseling a family on timelines; FAYUVI is not a therapy any outpatient clinic can administer, and the corticosteroid prophylaxis and liver-monitoring schedule requires coordination most primary practices will refer out for.
• Set expectations around the evidence honestly: Transpher A used an external natural-history comparison, not a randomized arm, on 27 treated patients — a real result in an ultra-rare disease, not a large trial.
• Don't assume insurance familiarity. At $3.95 million per patient, this is a novel prior-authorization conversation for most payers, and outcomes-based or value-based reimbursement arrangements were not public as of this approval.

What Isn’t Settled Yet

Ultragenyx set U.S. wholesale acquisition cost at $3.95 million per patient — a list price before any discounts, rebates or outcomes-based agreements, and one of the highest ever set for an approved therapy, trailing only a small handful of ultra-rare gene therapies priced above $4 million. None of those adjustments were public as of this approval. For a disease this rare, insurers have little precedent to draw on, and a family referred for treatment should expect a prior-authorization process that has not yet been worked out in practice, on top of a clinical timeline that already runs against a closing diagnostic window. Ultragenyx says product should reach qualified treatment centers within 30 to 60 days of approval — itself a logistical step, since administering the therapy safely requires the infusion capability and monitoring infrastructure the label assumes, which not every children's hospital yet has in place.

Frequently asked questions

What did FDA approve, and for whom?

On 17 September 2026, FDA granted standard approval to FAYUVI (rebisufligene etisparvovec-hopf, Ultragenyx) — a one-time intravenous AAV9 gene therapy delivering a working copy of the SGSH gene — for the neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function. It is the first FDA-approved treatment for the disease; until this approval, care was limited to managing symptoms as they appeared.

What does "preserved neurodevelopmental function" mean for eligibility?

The approval is not for every child with MPS IIIA — it is specifically for those who have not yet lost significant cognitive and developmental ground to the disease. Sanfilippo syndrome is progressive: children typically develop normally in infancy, then regress. FAYUVI's labeled population is defined by where a child sits on that decline, which makes early, accurate diagnosis — before regression is obvious — the determining factor in whether a child ever becomes eligible.

What did the Transpher A trial show?

The efficacy set: 27 treated patients (NCT02716246, dosed at 3x10^13 vg/kg) against an external natural-history cohort of 27 untreated patients, scoring 23.5 points higher on the Bayley-III cognitive raw score (p<0.0001). A separate 33-patient safety set was followed a median of 4.5 years, up to 8.5 years, and cerebrospinal fluid heparan sulfate fell by a median of 63.98% within the first month of treatment. FDA's standard, not accelerated, approval reflects that longer follow-up.

What does the infusion require, and what does it cost?

FAYUVI requires an infusion-capable setting and mandatory corticosteroid prophylaxis starting the day before infusion and continuing at least eight weeks after, to manage immune-mediated hepatotoxicity — elevated liver enzymes occurred in about 85% of treated patients in clinical studies. Ultragenyx set U.S. wholesale acquisition cost at $3.95 million per patient, among the highest list prices ever set for an approved therapy, with product expected to reach qualified treatment centers within 30 to 60 days of approval.